Colleen  Krause

Dr. Colleen Krause


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
SCSusanita Carvajal
Susanita Carvajal
SFSamantha N. Fera
Samantha N. Fera
AJAbby L. Jones
Abby L. Jones
TBThaisa A. Baldo
Thaisa A. Baldo
Islam MosaIslam Mosa
Islam Mosa
CKColleen Krause
Colleen Krause

7 September 2020 in Biosensors
Verified
Journal Article
Open access
PDF file
Lasangi DhanapalamudiyanselageLasangi Dhanapalamudiyanselage
Lasangi Dhanapalamudiyanselage
CKColleen Krause
Colleen Krause
AJAbby Jones
Abby Jones
James RuslingJames Rusling
James Rusling
Medical diagnostics is trending towards a more personalized future approach in which multiple tests can be digitized into patient records. In cancer diagnostics, patients can be tested for individual protein and genomic biomarkers that detect cancers at very early stages and also be used to monitor cancer progression or remission during therapy. These data can then be incorporated into patient records that could be easily accessed on a cell phone by a health care professional or the patients themselves on demand. Data on protein biomarkers have a large potential to be measured in point-of-care devices, particularly diagnostic panels that could provide a continually updated, personalized record of a disease like cancer. Electrochemical immunoassays have been popular among protein detection methods due to their inherent high sensitivity and ease of coupling with screen-printed and inkjet-printed electrodes. Integrated chips featuring these kinds of electrodes can be built at low cost and designed for ease of automation. Enzyme-linked immunosorbent assay (ELISA) features are adopted in most of these ultrasensitive detection systems, with microfluidics allowing easy manipulation and good fluid dynamics to deliver reagents and detect the desired proteins. Several of these ultrasensitive systems have detected biomarker panels ranging from four to eight proteins, which in many cases when a specific cancer is suspected may be sufficient. However, a grand challenge lies in engineering microfluidic-printed electrode devices for the simultaneous detection of larger protein panels (e.g., 50–100) that could be used to test for many types of cancers, as well as other diseases for truly personalized care.